Ribozymes as Potential Anti-HIV-1 Therapeutic Agents-Reference-Cited by-同舟云学术

Ribozymes as Potential Anti-HIV-1 Therapeutic Agents

Published:1990-03-09 Issue:4947 Volume:247 Page:1222-1225
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Sarver Nava¹,Cantin Edouard M.²,Chang Pairoj S.³⁴,Zaia John A.²,Ladne Paula A.²,Stephens Delilah A.²,Rossi John J.³

Affiliation:

1. Developmental Therapeutics Branch, Division of Research and Development Program, Division of AIDS, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892.

2. City of Hope Medical Center, Duarte, CA 91010.

3. Department of Molecular Genetics, Beckman Research Institute of the City of Hope, Duarte, CA 91010.

4. Department of Biochemistry, Loma Linda University, School of Medicine, Loma Linda, CA 92350.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference25 articles.

1. BUZAYAN, J.M., NONENZYMATIC CLEAVAGE AND LIGATION OF RNAS COMPLEMENTARY TO A PLANT-VIRUS SATELLITE RNA, NATURE 323: 349 (1986).

2. CECH, T.R., BIOLOGICAL CATALYSIS BY RNA, ANNUAL REVIEW OF BIOCHEMISTRY 55: 599 (1986).

3. CHANG, P.S., CLIN BIOTECHNOL 2: 1 (1990).

4. EPSTEIN, L.M., SELF-CLEAVING TRANSCRIPTS OF SATELLITE DNA FROM THE NEWT, CELL 48: 535 (1987).

5. FORSTER, A.C., SELF-CLEAVAGE OF PLUS AND MINUS RNAS OF A VIRUSOID AND A STRUCTURAL MODEL FOR THE ACTIVE-SITES, CELL 49: 211 (1987).

Cited by 650 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering of RNase P Ribozymes for Therapy against Human Cytomegalovirus Infection;Viruses;2024-07-25

2. The discovery of a catalytic RNA within RNase P and its legacy;Journal of Biological Chemistry;2024-06

3. Chemically Cross-Linked Hammerhead Ribozyme as an Efficient RNA Interference Tool;Journal of the American Chemical Society;2024-02-27

4. Eliminating the HIV tissue reservoir: current strategies and challenges;Infectious Diseases;2023-12-27

5. Multidimensional futuristic approaches to address the pandemics beyond COVID-19;Heliyon;2023-06